[go: up one dir, main page]

AR063458A1 - Derivados de piridina inhibidores de 11beta hsd1 - Google Patents

Derivados de piridina inhibidores de 11beta hsd1

Info

Publication number
AR063458A1
AR063458A1 ARP070104887A ARP070104887A AR063458A1 AR 063458 A1 AR063458 A1 AR 063458A1 AR P070104887 A ARP070104887 A AR P070104887A AR P070104887 A ARP070104887 A AR P070104887A AR 063458 A1 AR063458 A1 AR 063458A1
Authority
AR
Argentina
Prior art keywords
alkyl
ring
independently selected
halo
cyano
Prior art date
Application number
ARP070104887A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR063458A1 publication Critical patent/AR063458A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Reivindicacion 1: Un compuesto de formula (1):en el cual: Q es un enlace simple, -O-, -S- o -N(R15)-, donde R15 es hidrogeno, alquilo C1-3 o alcanoilo C2-3 o R15 y R1 junto con el átomo de nitrogeno al cual están unidos forman un anillo saturado de 4-7 miembros; R1 es alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, cicloalquil C3-7-alquilo C1-3, cicloalquil C3-7-alquenilo C2-3, cicloalquil C3-7-alquinilo C2-3, fenilo, fenilalquilo C1-3, heteroarilo, heteroarilalquilo C1-3, heterociclilo, o heterociclilalquilo C1-3 [cada uno de los cuales está sustituido en forma opcional con 1, 2 o :3 sustituyentes seleccionados en forma independiente de alquilo C1-3, hidroxi, halo, oxo, ciano, trifluorometilo, alcoxi C1-3, carboxialquilo C1-3, alquil C1-3S(O)n- (donde n es 0, 1, 2 o 3), R5CON(R5')-, (R5')(R5ö)NC(O)-, R5'C(O), R5OC(O)- y (R5')(R5ö)NSO2- (donde R5 es alquilo C1-3 sustituido nn forma opcional con 1, 2 o 3 sustituyentes seleccionados en forma independiente de hidroxilo, halo y ciano); y R5' y R5ö se seleccionan en forma independiente de hidrogeno y alquilo C1-3 sustituido en forma opcional con 1, 2 o 3 sustituyentes seleccionados en forma independiente de hidroxilo, halo, alcoxi C1-3, carboxi y ciano o R5' y R5ö junto con el átomo de nitrogeno al cual están unidos forman un anillo saturado de 4-7 miembros)] y los sustituyentes opcionales para el heterociclilo y el guipo heterociclilo en heterociclilalquilo C1-3 se seleccionan en forma adicional de R21, R21CO-R21S(O)k, (donde k es 0, 1 o 2) y R21CH2OC(O)- donde R21 es fenilo sustituido en forma opcional con 1 o 2 sustituyentes seleccionados en forma independiente de halo, hidroxi, ciano y trifluorometilo; o cuando Q es un enlace R1 puede también ser hidrogeno; R2 se selecciona de cicloalquil C3-7(CH2)m,- y policicloalquil C6-12(CH2)m- (donde los anillos cicloalquilo y policicloalquilo contienen en forma opcional 1 o 2 átomos en el anillo seleccionados en forma independiente de nitrogeno, oxigeno y azufre; m es 0, 1 o 2 y los anillos están sustituidos en forma opcional con 1, 2 o 3 sustituyentes seleccionados en forma independiente de R6); R3 se selecciona de hidrogeno, alquil C1-4-cicloalquilo C3-5 y cicloalquil C3-5-metilo; R2 y R3 junto con el átomo de nitrogeno al cual están unidos forman un sistema anular en puente, mono o bicíclico saturado que contiene en forma opcional 1 o 2 heteroátomos anulares adicionales seleccionados de nitrogeno, oxigeno y azufre y que está fusionado en forma opcional a un anillo saturado parcialmente saturado o insaturado, monocíclico, donde el sistema anular resultante está sustituido en forma opcional con 1, 2. o 3 sustituyentes seleccionados en forma independiente de R7; R4 se selecciona en forma independiente de halo, alquilo C1-2, ciano, alcoxi C1-2 y trifluorometilo; R6 y R7 se seleccionan en forma independiente de hidroxilo, halo, oxo, carboxi, ciano, trifluorometilo, R9, R9O-, R9CO-, R9C(O)O-, R9CON(R9')-, (R9')(R9ö)NC(O)-, (R9')(R9ö)N-, R9S(O)a-, donde a es 0 hasta 2, R9'OC(O)-, (R9')(R9ö)NSO2-, R9SO2N(R9')-, (R9')(R9ö)NC(O)N(R9ö)-, fenilo y heteroarilo [donde los grupos fenilo y heteroarilo están fusionados en forma opcional a un fenilo, heteroarilo o un anillo de 5 o 6 miembros saturado o parcialmente saturado que contiene en forma opcional 1, 2 o 3 heteroátomos seleccionados en forma independiente de nitrogeno, oxigeno y azufre y el sistema anular resultante está sustituido en forma opcional con 1, 2 o 3 sustituyentes seleccionados en forma independiente de alquilo C1-4, hidroxilo, ciano, trifluorometilo, trifluorometoxi, halo, alcoxi C1-4, alcoxi C1-4-alquilo C1-4, alcoxi C1-4-aIquilo C1-4, amino, N- alquilamino C1-4, di-N,N-(alquil C1-4)amino, N-alquilcarbamoilo C1-4, di-N,N-(alquil C1-4)carbamoílo, alquil C1-4S(O)r-, alquil C1-4S(O)r-alquilo C1-4 (donde r es 0, 1 y 2)];R9 es en forma independiente alquilo C1-3 suslituido en forma opcional con 1, 2 o 3 sustituyentes seleccionados en forma independiente de hidroxilo, halo, alcoxi C1-4, carboxi y ciano; R9', R9ö y 9'öse seleccionan en forma independiente de hidrogeno y alquilo C1-3 sustituido en forma opcional con hidroxilo, halo, alcoxi C1- 4, carboxi o ciano; p es 0, 1 o 2; cualquier X es -O(CH2)q-, S(CH2)q- o -N(R12)(CH2)q-, donde R12 es hidrogeno, alquilo C1-3 o alcanoilo C1-3 y q es 0 o 1; e Y es: 1) un anillo cicloalquidilo C3-7, un anillo fenileno, un grupo adamantidilo, un anillo heterociclilo saturado de 5-7 miembros (conectado por un átomo de carbono del anillo) que contiene 1 o 2 heteroátomos en el anillo seleccionados nitrogeno, oxígeno y azufre, o -[C(Rx)(Ry)]v- (donde Rx y Ry se seleccionan en forma independiente de hidrogeno, alquilo C1-3, alcoxi C1-3 e hidroxilo o Rx y Ry junto con el átomo de carbono al cual están unidos forman un anillo cicloalquidilo C3-7 y v es 1, 2, 3, 4 o 5) y cuando y es mayor que 1 el grupo [C(Rx)(Ry)]v- puede estar interrumpido en forma opcional por un grupo -O-, -S- o -N(R20)-, donde R20 es hidrogeno o alquilo C1-3; o 2) -X-Y- juntos representan un grupo de formula (2) en el cual el anillo A está conectado con el grupo piridina y (Z)t[C(R13)(R14)]s- está conectado con el grupo carboxi; y A es un sistema anular mono-, bi- o espiro-heterocíclico de 4-7 miembros que contiene un átomo de nitrogeno del anillo por el cual está unido al anillo de piridina y en forma adicional y opcional otro heteroátomo del anillo seleccionado de nitrogeno, oxígeno y azufre; Z es -O-, -S- o -N(R16)- donde R16 es hidrogeno, alquilo C1-3 o alcanoilo C1-3; t es 0 o 1 siempre que cuando s es 0 entonces t es 0; R10 se selecciona en forma independiente de alquilo C1-3, alquenilo C2-3, alquinilo C2-3, hidroxi, halo, oxo, ciano, trifluorometilo alcoxi C1-3, alquil C1-3S(O)n- (donde n es 0, 1, 2 o 3), R11CON(R 11'), (R11')(R11ö)NC(O)-, R11'OC(O)- y (R11')(R11ö)NSO2- (donde R11 es alquilo C1-3 sustituido en forma opcional con hidroxilo, halo o ciano; y R11' y R11ö se seleccionan en forma independiente de hidrogeno y alquilo C1-3 sustituido en forma opcional con hidroxilo, halo, alcoxi C1-3, carboxi o ciano) o R11' y R11ö junto con el átomo de nitrogeno al cual están unidos forman un anillo de 4-7 miembros; u es 0, 1 o 2; R13 y R14 se seleccionan en forma independiente de hidrogeno y alquilo C1-3 o R13 y R14 pueden formar, junto con el átomo de carbono al cual están unidos, un anillo cicloalquilo C3- 7; y s es 0, 1 o 2; o una de sus sales o sus ésteres hidrolizables in vivo aceptable desde el punto de vista farmacéutico; siempre que el compuesto no sea: ácido {(3S)-1-[5-(adamantan-1-ilcarbamoil)piridin-2-il]piperidin-3-il}acético; o ácido {(3S)- 1-[5-(ciclohexilcarbamoil)-6-(piperazin-1-il)piridin-2-il]piperidin-3-il}acético; o una de sus sales o sus ésteres hidrolizables in vivo aceptables desde el punto de vista farmacéutico.
ARP070104887A 2006-11-03 2007-11-02 Derivados de piridina inhibidores de 11beta hsd1 AR063458A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86424706P 2006-11-03 2006-11-03
US86430306P 2006-11-03 2006-11-03

Publications (1)

Publication Number Publication Date
AR063458A1 true AR063458A1 (es) 2009-01-28

Family

ID=39304797

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104887A AR063458A1 (es) 2006-11-03 2007-11-02 Derivados de piridina inhibidores de 11beta hsd1

Country Status (30)

Country Link
US (3) US7964618B2 (es)
EP (2) EP2233480B1 (es)
JP (1) JP5165688B2 (es)
KR (1) KR101465275B1 (es)
CN (3) CN101787016B (es)
AR (1) AR063458A1 (es)
AT (1) ATE475649T1 (es)
AU (1) AU2007315955B2 (es)
BR (1) BRPI0717970C1 (es)
CA (1) CA2668006C (es)
CL (1) CL2007003176A1 (es)
CO (1) CO6321130A2 (es)
CY (1) CY1110813T1 (es)
DE (1) DE602007008137D1 (es)
DK (1) DK2086939T3 (es)
ES (2) ES2347491T3 (es)
HR (1) HRP20100522T1 (es)
IL (1) IL198231A0 (es)
MX (1) MX2009004707A (es)
NO (1) NO20091603L (es)
NZ (1) NZ576501A (es)
PE (1) PE20081487A1 (es)
PL (1) PL2086939T3 (es)
PT (1) PT2086939E (es)
RS (1) RS51451B (es)
RU (1) RU2451674C2 (es)
SI (1) SI2086939T1 (es)
TW (1) TW200827346A (es)
UY (1) UY30681A1 (es)
WO (1) WO2008053194A2 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1953145B1 (en) 2005-11-21 2015-11-04 Shionogi & Co., Ltd. Heterocyclic compound having inhibitory activity on 11-b-hydroxysteroid dehydrogenase type i
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
TW200836719A (en) * 2007-02-12 2008-09-16 Astrazeneca Ab Chemical compounds
EP2163543B1 (en) 2007-05-18 2015-03-04 Shionogi&Co., Ltd. Nitrogen-containing heterocyclic derivative having 11 beta-hydroxysteroid dehydrogenase type i inhibitory activity
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2202228B1 (en) * 2007-10-15 2014-12-10 Takeda Pharmaceutical Company Limited Amide compounds and use of the same
WO2009056881A1 (en) * 2007-10-29 2009-05-07 Astrazeneca Ab Chemical compounds 313
JP2011510966A (ja) * 2008-02-04 2011-04-07 アストラゼネカ アクチボラグ ４−［４−（２−アダマンチルカルバモイル）−５−ｔｅｒｔ−ブチル−ピラゾル−１−イル］安息香酸の新規な結晶形態
UY31774A (es) * 2008-04-22 2009-12-14 Astrazeneca Ab Compuestos de 2-pirimidin-5- ilcarboxamida sustituidos
EP2243479A3 (en) 2009-04-20 2011-01-19 Abbott Laboratories Novel amide and amidine derivates and uses thereof
ES2444777T3 (es) 2009-06-12 2014-02-26 Bristol-Myers Squibb Company Compuestos de nicotinamida útiles como moduladores de quinasas
UY32954A (es) * 2009-10-20 2011-05-31 Astrazeneca Ab PIRIMIDINAS SUSTITUIDAS CON ADAMANTILIMINOCARBONILO COMO INHIBIDORES DE 11-ß-HSD1 826?.
KR20120098796A (ko) * 2009-11-24 2012-09-05 알러간, 인코포레이티드 치료적 유용성을 지니는 수용체 조절제로서의 신규한 화합물
US8871208B2 (en) * 2009-12-04 2014-10-28 Abbvie Inc. 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
KR20110123657A (ko) * 2010-05-07 2011-11-15 에스케이케미칼주식회사 피콜린아마이드 및 피리미딘-4-카복사미드 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
CN103180321A (zh) 2010-09-23 2013-06-26 Abbvie公司 氮杂金刚烷衍生物的一水合物
US8471027B2 (en) * 2011-04-06 2013-06-25 Hoffmann-La Roche Inc. Adamantyl compounds
WO2013010382A1 (zh) * 2011-07-21 2013-01-24 山东亨利医药科技有限责任公司 杂环取代的嘧啶类化合物
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN102659657B (zh) * 2012-04-24 2014-08-06 徐州医学院 一种蛋白酶抑制剂pf429242的合成方法
KR20150021057A (ko) 2012-06-20 2015-02-27 에프. 호프만-라 로슈 아게 Lpar 길항제로서의 n-알킬트라이아졸 화합물
CN104411690A (zh) 2012-06-20 2015-03-11 霍夫曼-拉罗奇有限公司 作为lpar拮抗剂的取代的吡唑化合物
EP3821892A1 (en) * 2019-11-12 2021-05-19 University of Leeds (s)-2-(1-(5-(cyclohexylcarbamoyl)-6-(propylthio)pyridin-2-yl)piperidin-3-yl) acetic acid for use in treating wounds
GB202216324D0 (en) * 2022-11-02 2022-12-14 Cerevance Ltd Novel compounds
GB202408335D0 (en) 2024-06-11 2024-07-24 Astrazeneca Ab Therapies for wound treatment

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR66581B (es) 1978-02-21 1981-03-27 Delalande Sa
US4734418A (en) 1984-12-14 1988-03-29 Mitsui Petrochemical Industries, Ltd. Quinazoline compounds and antihypertensives
TR200200701T2 (tr) 1999-09-16 2002-06-21 Tanabe Seiyaku Co., Ltd. Altı-elementli aromatik nitrojenli halka bileşimleri.
FR2803592A1 (fr) * 2000-01-06 2001-07-13 Aventis Cropscience Sa Nouveaux derives de l'acide 3-hydroxypicolinique, leur procede de preparation et compositions fongicides les contenant.
US7273868B2 (en) 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
WO2002020463A2 (en) 2000-09-05 2002-03-14 Tularik Inc. Fxr modulators
DK1383731T3 (da) 2000-10-20 2009-12-07 Biocryst Pharm Inc Biarylforbindelser som serinproteaseinhibitorer
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
JP2005528395A (ja) 2002-04-05 2005-09-22 ザ ユニバーシティ オブ エディンバラ 組成物
WO2004039795A2 (en) * 2002-10-29 2004-05-13 Fujisawa Pharmaceutical Co., Ltd. Amide compounds for the treatment of hyperlipidemia
TW200503994A (en) 2003-01-24 2005-02-01 Novartis Ag Organic compounds
SE0300458D0 (sv) * 2003-02-19 2003-02-19 Astrazeneca Ab Novel compounds
SE0300457D0 (sv) * 2003-02-19 2003-02-19 Astrazeneca Ab Novel compounds
NZ541824A (en) 2003-02-26 2010-04-30 Banyu Pharma Co Ltd Heteroarylcarbamoylbenzene derivatives as glucokinase activators
WO2004089896A1 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS
WO2005016877A2 (en) 2003-08-07 2005-02-24 Merck & Co., Inc. Pyrazole carboxamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
BRPI0414313A (pt) 2003-09-11 2006-11-07 Kemia Inc inibidores de citocinas
GB0327761D0 (en) 2003-11-29 2003-12-31 Astrazeneca Ab Compounds
OA13344A (en) 2003-12-19 2007-04-13 Pfizer Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-HSD-1) for the treatment of diabetes and obesity.
ATE407119T1 (de) 2004-02-24 2008-09-15 Glaxo Group Ltd Pyridinderivate und deren verwendung als modulatoren des cb2-rezeptors
CA2561791A1 (en) * 2004-03-31 2005-10-20 Janssen Pharmaceutica, N.V. Non-imidazole heterocyclic compounds
EP1745019A1 (en) 2004-05-06 2007-01-24 Pfizer Inc. Novel compounds of proline and morpholine derivatives
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
JP4809339B2 (ja) 2004-06-28 2011-11-09 エフ．ホフマン−ラ ロシュ アーゲー ピリミジン誘導体
EP1812407A2 (en) 2004-11-02 2007-08-01 Pfizer, Inc. Novel compounds of substituted and unsubstituted adamantyl amides
US7767680B2 (en) 2004-11-03 2010-08-03 Vertex Pharmaceuticals Incorporated Ion channel modulators and methods of use
ATE555081T1 (de) 2005-01-05 2012-05-15 Abbott Lab Adamantyl-derivate als inhibitoren des 11-beta- hydroxysteroid-dehydrogenase-1-enzyms
AU2006232660B2 (en) 2005-04-05 2010-03-25 F. Hoffmann-La Roche Ag 1H-Pyrazole 4-Carboxylamides, their preparation and their use as 11Beta-hydroxysteroid dehydrogenase
ES2326280T3 (es) 2005-04-06 2009-10-06 F. Hoffmann-La Roche Ag Derivados de piridin-3-carboxamida como agonistas inversos de cb1.
WO2006106423A2 (en) 2005-04-07 2006-10-12 Pfizer Inc. Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase
EP2527337A1 (en) 2005-04-14 2012-11-28 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
US20110059941A1 (en) 2005-05-24 2011-03-10 Peter William Rodney Caulkett 2-phenyl substituted imidazol [4,5b] pyridine/pyrazine and purine derivatives as glucokinase modulators
EP1894919B1 (en) 2005-06-07 2012-03-28 Shionogi & Co., Ltd. Heterocyclic compound having type i 11 beta hydroxysteroid dehydrogenase inhibitory activity
AU2006255944B2 (en) 2005-06-08 2010-03-04 Japan Tobacco Inc. Heterocyclic compound
MX2007016319A (es) 2005-06-16 2008-03-10 Pfizer Derivados de n-(piridin-2-il)-sulfonamida.
JP4651714B2 (ja) 2005-07-09 2011-03-16 アストラゼネカ アクチボラグ 糖尿病の治療においてｇｌｋ活性化剤として使用するためのヘテロアリールベンズアミド誘導体
WO2007017649A1 (en) 2005-08-09 2007-02-15 Astrazeneca Ab Heteroarylcarbamoylbenzene derivatives for the treatment of diabetes
CA2627813A1 (en) 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Substituted pyrrolones as allosteric modulators of glucokinase
WO2007052843A1 (ja) 2005-11-04 2007-05-10 Takeda Pharmaceutical Company Limited 複素環アミド化合物およびその用途
EP1953145B1 (en) 2005-11-21 2015-11-04 Shionogi & Co., Ltd. Heterocyclic compound having inhibitory activity on 11-b-hydroxysteroid dehydrogenase type i
KR20080091503A (ko) 2006-01-31 2008-10-13 인사이트 코포레이션 아미도 화합물 및 약제로서의 이의 용도
BRPI0708974A2 (pt) 2006-03-22 2011-06-21 Hoffmann La Roche composto, composição farmacêutica, métodos de tratamento de diabetes, obesidade ou sìndrome metabólica e uso do composto
CN101448782A (zh) 2006-04-07 2009-06-03 高点制药有限责任公司 对1型11β-羟基甾体脱氢酶具有活性的化合物
AU2007245734A1 (en) 2006-04-27 2007-11-08 Solvay Pharmaceuticals Gmbh Use of CBX cannabinoid receptor modulators as potassium channel modulators
US20100022589A1 (en) 2006-07-27 2010-01-28 Mccoull William Pyridine-3-carboxamide compounds and their use for inhibiting 11-beta-hydroxysteroid dehydrogenase
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
TW200836719A (en) 2007-02-12 2008-09-16 Astrazeneca Ab Chemical compounds
EP2163543B1 (en) 2007-05-18 2015-03-04 Shionogi&Co., Ltd. Nitrogen-containing heterocyclic derivative having 11 beta-hydroxysteroid dehydrogenase type i inhibitory activity
ES2423181T3 (es) 2007-07-17 2013-09-18 F. Hoffmann-La Roche Ag Inhibidores de la 11ß-hidroxiesteroide-deshidrogenasa
EP2217232A1 (en) 2007-11-06 2010-08-18 AstraZeneca AB 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid - 465
JP2011510966A (ja) 2008-02-04 2011-04-07 アストラゼネカ アクチボラグ ４−［４−（２−アダマンチルカルバモイル）−５−ｔｅｒｔ−ブチル−ピラゾル−１−イル］安息香酸の新規な結晶形態
UY31774A (es) 2008-04-22 2009-12-14 Astrazeneca Ab Compuestos de 2-pirimidin-5- ilcarboxamida sustituidos
EP2391607A1 (en) 2009-01-30 2011-12-07 AstraZeneca AB Novel process for preparing carboxy-containing pyrazoleamido compounds 597
UY32954A (es) 2009-10-20 2011-05-31 Astrazeneca Ab PIRIMIDINAS SUSTITUIDAS CON ADAMANTILIMINOCARBONILO COMO INHIBIDORES DE 11-ß-HSD1 826?.

Also Published As

Publication number Publication date
DK2086939T3 (da) 2010-10-11
EP2086939A2 (en) 2009-08-12
DE602007008137D1 (en) 2010-09-09
RU2009115830A (ru) 2010-12-10
BRPI0717970A2 (pt) 2013-11-05
CN101787016B (zh) 2013-08-28
MX2009004707A (es) 2009-05-15
NZ576501A (en) 2011-03-31
ATE475649T1 (de) 2010-08-15
WO2008053194A3 (en) 2008-10-02
BRPI0717970C1 (pt) 2021-05-25
TW200827346A (en) 2008-07-01
HK1135090A1 (en) 2010-05-28
CL2007003176A1 (es) 2008-07-25
CN101573336B (zh) 2012-03-21
US7964618B2 (en) 2011-06-21
AU2007315955B2 (en) 2011-04-14
CA2668006A1 (en) 2008-05-08
ES2347491T3 (es) 2010-10-29
CN101787016A (zh) 2010-07-28
RS51451B (sr) 2011-04-30
EP2086939B1 (en) 2010-07-28
CA2668006C (en) 2016-05-24
PE20081487A1 (es) 2009-01-11
AU2007315955A1 (en) 2008-05-08
JP5165688B2 (ja) 2013-03-21
CN101573336A (zh) 2009-11-04
HRP20100522T1 (hr) 2010-11-30
US20090306075A1 (en) 2009-12-10
IL198231A0 (en) 2009-12-24
US20090312372A1 (en) 2009-12-17
RU2451674C2 (ru) 2012-05-27
KR20090075865A (ko) 2009-07-09
KR101465275B1 (ko) 2014-11-27
SI2086939T1 (sl) 2010-10-29
UY30681A1 (es) 2008-07-03
PL2086939T3 (pl) 2011-09-30
PT2086939E (pt) 2010-09-17
US8673938B2 (en) 2014-03-18
BRPI0717970B8 (pt) 2020-12-01
JP2010508338A (ja) 2010-03-18
EP2233480A1 (en) 2010-09-29
US20080269288A1 (en) 2008-10-30
ES2423206T3 (es) 2013-09-18
CY1110813T1 (el) 2015-06-10
BRPI0717970B1 (pt) 2019-10-22
EP2233480B1 (en) 2013-05-29
WO2008053194A2 (en) 2008-05-08
NO20091603L (no) 2009-05-28
CN102603711A (zh) 2012-07-25
CO6321130A2 (es) 2011-09-20
EP2086939B8 (en) 2011-06-22

Similar Documents

Publication Publication Date Title
AR063458A1 (es) Derivados de piridina inhibidores de 11beta hsd1
AR074902A1 (es) Derivados de 1,2,4-oxadiazoles agonistas de receptores s1p1
AR053232A1 (es) Derivados de piridina condensadas, composiciones farmaceuticas que los contienen y su empleo en la fabricacion de agentes terapeuticos antiinflamatorios y para el tratamiento de enfermedades relacionadas con el sistema inmunologico.
AR065300A1 (es) Compuestos quimicos derivados de 1,2-pirazol
AR046244A1 (es) Activadores de glucoquinasa heteroaromaticos de seis miembros 5- sustituidos
KR927003052A (ko) 2-아릴티아졸 유도체 및 그의 약제학적 조성물
AR078168A1 (es) Derivados de piperidinas y piperazinas, procesos para prepararlos y sus usos como moduladores de gpr119
CO6220931A2 (es) Inhibidores de serina proteasas para el tratamiento de infecciones de vhc
AR056109A1 (es) Derivados de tiazolopiridina como activadores de la actividad de glucoquinasa
PE20171177A1 (es) Compuestos aminopirimidinilo inhibidores de jak
AR015765A1 (es) Dihidropirimidinas 2 heterociclicamente sustituidas, proceso para su preparacion, medicamentos que los contienen, proceso para la preparacion de los mismosuso de dichos dihidropirimidinas para la preparacion de un medicamento.
ES2572148T3 (es) Un método para el tratamiento de la enfermedad de Pompe usando 1-desoxinojirimicina y derivados
AR057769A1 (es) Pirazolo pirimidinas como inhibidores de map quinasa p38, metodos para utilizarlos y composiciones farmaceuticas
AR051202A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
AR040336A1 (es) Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para preparar dicho compuesto
AR055144A1 (es) Inhibidor de secrecion acida
AR047056A1 (es) Derivados de pirimidinas condensadas. composiciones farmacéuticas
AR062677A1 (es) Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden
MX2009007954A (es) Derivado de heterocicliden-n-(aril) acetamida.
PE20140161A1 (es) Compuesto biciclico
CA2514191A1 (en) Compound inhibiting dipeptidyl peptidase iv
EA200800484A1 (ru) Макроциклические ингибиторы вируса гепатита с
EA200800478A1 (ru) Макроциклические ингибиторы вируса гепатита с
AR062258A1 (es) Compuestos heterociclicos condensados de tieno-pirrol, composiciones farmaceuticas que los contienen y usos para el tratamiento de infecciones por hcv
AR064517A1 (es) Pirimidinionas biciclicas y sus usos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal